William Bowen, MD
Cardiovascular Disease · Saint Louis, MONPI 1609815950
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $723,632 of the $725,918 with a category attached, or 99.7%. Boehringer Ingelheim accounts for 99.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $723,632 and has fallen 100.0% since, to $40 in 2024. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 166 payments — averaging $4373.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$724K
- AbbVie$441
- AstraZeneca$254
- Novo Nordisk$229
- Pfizer$206
- Lilly USA, LLC$167
- plus $805 from 14 others
Across 3 payments — averaging $234,006 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$702K
- Eli Lilly$21
What the payments were for
- Speaking & faculty fees$723,632100%
- Food & beverage$2,2420%
- Education$210%
- Other$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 25 | $723,814 |
| AbbVie(2 entities) | 24 | $441 |
| AstraZeneca | 20 | $254 |
| Novo Nordisk | 17 | $229 |
| Pfizer | 17 | $206 |
| Lilly USA, LLC | 13 | $167 |
| Amgen | 6 | $109 |
| Sanofi-aventis U.S. LLC | 5 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $82 |
| Amarin Pharma, Inc. | 5 | $74 |
| Johnson & Johnson | 4 | $71 |
| Astellas Pharma US Inc | 3 | $68 |
| Novartis | 5 | $65 |
| GSK | 5 | $59 |
| Arbor Pharmaceuticals, Inc. | 4 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Shire North American Group Inc | 2 | $32 |
| Recor Medical Inc | 1 | $23 |
| Welch Allyn | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$725,918 in reported general payments places this provider in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 176 | $172,576 |
| XareltoRivaroxaban | 53 | $61,750 |
| JardianceEmpagliflozin | 38 | $44,529 |
| OzempicSemaglutide | 19 | $27,483 |
| MounjaroTirzepatide | 26 | $25,812 |
| EntrestoSacubitril/Valsartan | 17 | $15,105 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 50 | $13,303 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,626 |
| MyrbetriqMirabegron | 12 | $8,194 |
| LinzessLinaclotide | 12 | $7,197 |
| BrilintaTicagrelor | 13 | $6,539 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $6,351 |
| Arnuity ElliptaFluticasone Furoate | 11 | $5,281 |
| VascepaIcosapent Ethyl | 12 | $4,838 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $206 | $172,576176 claims |
| Johnson & JohnsonXarelto | $71 | $61,75053 claims |
| Boehringer IngelheimJardiance | $723,814 | $44,52938 claims |
| GSKArexvy, Trelegy Ellipta, Incruse Ellipta, Arnuity Ellipta, Breo Ellipta | $59 | $38,361104 claims |
| Novo NordiskOzempic | $229 | $27,48319 claims |
| Lilly USA, LLCMounjaro | $167 | $25,81226 claims |
| NovartisEntresto | $65 | $15,10517 claims |
| AbbVieLinzess, Creon, Synthroid | $441 | $11,61858 claims |
| Astellas Pharma US IncMyrbetriq | $68 | $8,19412 claims |
| AstraZenecaBrilinta | $254 | $6,53913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Louis
- Georges ChahoudSaint Louis$937K
- Daniel KellySaint Louis$582K
- Osler Jay GuzonSaint Louis$211K
- Mohammad TahirSaint Louis$173K
- Robert RifkinSaint Louis$145K
- Martin SchwarzeSaint Louis$113K
- Joshua MitchellSaint Louis$103K
- Zainab MahmoudSaint Louis$100K
- Nizar AssiSaint Louis$81K
- Mustafa HusainiSaint Louis$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.